Literature DB >> 17058754

Symptom prevalence and severity in people severely affected by multiple sclerosis.

Irene J Higginson1, Sam Hart, Eli Silber, Rachel Burman, Polly Edmonds.   

Abstract

AIM: This study sought to assess symptom severity and prevalence in people severely affected by multiple sclerosis (MS).
METHODS: We collected data on symptoms and problems of patients as self-reported to trained interviewers on standardized questionnaires (including the Palliative Outcome Scale MS symptom checklist, POS-MSS).
RESULTS: 52 patients were included, mean age 53 years; 26 had secondary progressive MS, 23 had primary progressive MS, three had other forms; 32/52 were unable to walk independently. Patients reported a mean of nine (median = 8.5, mode = 12) symptoms. Six symptoms affected more than 50% of patients: problems using legs, problems using arms, fatigue/lack of energy, spasms, pain, and feeling sleepy. Higher levels of disability were correlated with greater symptom severity for nine symptoms (Spearman rho ranged 0.28-0.56, p < 0.05).
CONCLUSION: Many symptoms in people severely affected by MS are as highly prevalent and severe as those experienced by patients with advanced cancer. Increased disability is associated with increased severity for some symptoms.

Entities:  

Mesh:

Year:  2006        PMID: 17058754

Source DB:  PubMed          Journal:  J Palliat Care        ISSN: 0825-8597            Impact factor:   2.250


  27 in total

1.  The effect of CTAB, a cationic surfactant, on the absorption rate of [14C]tripalmitate from a test meal in the rat.

Authors:  B Isomaa; G Sjöblom
Journal:  Food Cosmet Toxicol       Date:  1975-10

2.  Palliative and end-of-life care in advanced Parkinson's disease and multiple sclerosis.

Authors:  Colin W Campbell; Edward J S Jones; Jane Merrills
Journal:  Clin Med (Lond)       Date:  2010-06       Impact factor: 2.659

3.  Palliative care for severely affected patients with multiple sclerosis: when and why? Results of a Delphi survey of health care professionals.

Authors:  Julia Strupp; Vanessa Romotzky; Maren Galushko; Heidrun Golla; Raymond Voltz
Journal:  J Palliat Med       Date:  2014-07-28       Impact factor: 2.947

4.  How can we improve outcomes for patients and families under palliative care? Implementing clinical audit for quality improvement in resource limited settings.

Authors:  Lucy Selman; Richard Harding
Journal:  Indian J Palliat Care       Date:  2010-01

Review 5.  Current management of pain associated with multiple sclerosis.

Authors:  Walter Pöllmann; Wolfgang Feneberg
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

6.  Cross-Sectional Examination of the Associations Between Symptoms, Community Integration, and Mental Health in Multiple Sclerosis.

Authors:  Anna L Kratz; Dawn M Ehde; Marisol A Hanley; Mark P Jensen; Travis L Osborne; George H Kraft
Journal:  Arch Phys Med Rehabil       Date:  2015-10-31       Impact factor: 3.966

7.  Case Report: Effect of Antigravity Treadmill Training on Muscle Oxidative Capacity, Muscle Endurance, and Walking Function in a Person with Multiple Sclerosis.

Authors:  T Bradley Willingham; Jonathan Melbourn; Marina Moldavskiy; Kevin K McCully; Deborah Backus
Journal:  Int J MS Care       Date:  2018 Jul-Aug

8.  Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors.

Authors:  Irene J Higginson; Wei Gao; Tariq Zaffer Saleem; K Ray Chaudhuri; Rachel Burman; Paul McCrone; Peter Nigel Leigh
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

9.  Developing brief fatigue short forms calibrated to a common mathematical metric: is content-balancing important?

Authors:  Karon F Cook; Seung W Choi; Kurt L Johnson; Dagmar Amtmann
Journal:  Patient Relat Outcome Meas       Date:  2010-08

Review 10.  Palliative Care Intervention Trials for Adults Living With Progressive Central Nervous System Diseases and Their Caregivers: A Systematic Review.

Authors:  HeatherE Leeper; Diane Cooper; TerriS Armstrong
Journal:  J Pain Symptom Manage       Date:  2021-06-18       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.